Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.

Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D.

PLoS Pathog. 2016 Mar 31;12(3):e1005483. doi: 10.1371/journal.ppat.1005483. eCollection 2016 Mar.

2.

Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.

Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D.

Vaccine. 2015 Nov 27;33(48):6611-6. doi: 10.1016/j.vaccine.2015.10.091. Epub 2015 Nov 1.

PMID:
26529068
3.

Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Papic N, Schuitemaker H, Custers JHHV.

Vaccine. 2015 Oct 13;33(42):5498-5502. doi: 10.1016/j.vaccine.2015.08.081. Epub 2015 Sep 9.

PMID:
26362098
4.

Brunenders: a partially attenuated historic poliovirus type I vaccine strain.

Sanders BP, Liu Y, Brandjes A, van Hoek V, de Los Rios Oakes I, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D.

J Gen Virol. 2015 Sep;96(9):2614-22. doi: 10.1099/vir.0.000197. Epub 2015 May 26.

PMID:
26018960
5.

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H.

Vaccine. 2013 Jan 21;31(5):850-6. doi: 10.1016/j.vaccine.2012.10.070. Epub 2012 Oct 30.

PMID:
23123018
6.

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA.

Vaccine. 2008 Jun 2;26(23):2818-23. doi: 10.1016/j.vaccine.2008.03.080. Epub 2008 Apr 16.

PMID:
18455276
7.

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr.

Infect Immun. 2007 May;75(5):2283-90. Epub 2007 Feb 16.

8.

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ.

PLoS Med. 2006 Jun;3(6):e177. Epub 2006 May 16.

9.

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH.

J Immunol. 2005 Jun 1;174(11):7179-85.

10.

Isolation and characterisation of a class of carbohydrate oxidases from higher plants, with a role in active defence.

Custers JH, Harrison SJ, Sela-Buurlage MB, van Deventer E, Lageweg W, Howe PW, van der Meijs PJ, Ponstein AS, Simons BH, Melchers LS, Stuiver MH.

Plant J. 2004 Jul;39(2):147-60.

11.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

12.

T-DNA tagging of a pathogen inducible promoter in Arabidopsis thaliana.

Custers JH, Melchers LS, Tigelaar H, Bade JB, Spiegeler JJ, van Der Meijs PJ, Simons BH, Stuiver MH.

Mol Plant Pathol. 2002 Jul 1;3(4):239-49. doi: 10.1046/j.1364-3703.2002.00115.x.

PMID:
20569331
13.

Engineering disease resistance in plants.

Stuiver MH, Custers JH.

Nature. 2001 Jun 14;411(6839):865-8. Review.

PMID:
11459071
14.

[Myxedema and congestive heart failure].

Custers JH.

Ned Tijdschr Geneeskd. 1970 Oct 17;114(42):1738-41. Dutch. No abstract available.

PMID:
5506432
15.

[A patient with 2 malignant disorders].

Custers JH.

Ned Tijdschr Geneeskd. 1969 Aug 2;113(31):1352-4. Dutch. No abstract available.

PMID:
4184550
16.

Failure to detect interfering agents in febrile respiratory illnesses.

Custers JH, van der Veen J.

Antonie Van Leeuwenhoek. 1967;33(2):213-9. No abstract available.

PMID:
4291665

Supplemental Content

Loading ...
Support Center